双嘧达莫与阿魏酸钠联合应用治疗糖尿病肾病临床观察

Clinical observation of Dipyridamole and Sodium Ferulate in treatment of diabetes nephrosis

目的:观察双嘧达莫与阿魏酸钠联合应用治疗糖尿病肾病(DN)患者尿白蛋白排泄率(UAER)、血肌酐(SCr)、尿素氮(BUN)、尿内皮素(ET-1)水平的变化。方法:60例DN患者在糖尿病常规治疗、皮下注射胰岛素等基础上,加用双嘧达莫(30mg/d)和阿魏酸钠(300mg/d),分别加入生理盐水200ml中静滴,治疗4周。结果:经治疗后,患者UAER、SCr、BUN、ET-1均较治疗前显著下降(均P<0.01)。结论:双嘧达莫能抑制血小板功能,还具有扩张血管、增加肾脏血流量、减少蛋白尿、保护肾脏的作用。阿魏酸钠可以通过拮抗ET受体、抑制TXA2合成、降低TGF-β、清除自由基、减少炎症介质生成及调节免疫等作用来延缓肾脏损害。两药合用治疗DN疗效显著。

Objective： To observe the level changes of urinate albumin excretion rate （UAER）, serum creatinine （SCr）, urea nitrogen （BUN）, the urine bast element （ET-1） of diabetes nephrosis （DN） patients treated by Dipyridamole and Sodium Fer ulate. Methods： 60 cases of DN patients were given Dipyridamole （30 mg/d） and Sodium Ferulate （300 mg/d） based on the diabetes convention treatment and hypodermic Injection Insulin, Dipyridamole and Sodium Ferulate was added into the 200 ml Physiological Saline respectively and intravenous drip, the time of treatment was 4 weeks. Results： After treatment, the UAER, SCr, BUN, ET-1 of patients remarkablely dropped compared with before treatment （all P0.01）. Conclusion： Dipyridamole could suppress the blood platelet function, but also has the expansion of blood vessel, increase the kidney blood stream quantity, reduce the albuminuria, protect the kidney; the Sodium Ferulate may oppress the anti-ET acceptor, suppress the TXA2 synthesis, reduce TGF-β, eliminate free radical, reduce inflammation functions and so on medium production and adjust immunity to delay the kidney harm. And the curative effect is remarkable in the treatment of DN patients with both of them.